Showing results (41-50 of 64) with videos related to
Sort By:
Pageof 7
Plos Computational Biology|March 23, 2012
Highly sensitive and specific detection of rare variants in mixed viral populations from massively parallel sequence dataAlexander R Macalalad, Michael C Zody, Patrick Charlebois, et al.Journal of Virology|November 18, 2011
High-resolution analysis of intrahost genetic diversity in dengue virus serotype 1 infection identifies mixed infectionsKhoa T D Thai, Matthew R Henn, Michael C Zody, et al.Journal of Virology|September 2, 2011
Compensatory mutations restore the replication defects caused by cytotoxic T lymphocyte escape mutations in hepatitis C virus polymeraseCesar Oniangue-Ndza, Thomas Kuntzen, Michael Kemper, et al.Environmental Microbiology|July 29, 2010
Genomic analysis of oceanic cyanobacterial myoviruses compared with T4-like myoviruses from diverse hosts and environmentsMatthew B Sullivan, Katherine H Huang, Julio C Ignacio-Espinoza, et al.The Journal of Infectious Diseases|August 2, 2025
Comparability of gastrointestinal microbiome and bile acid profiles in patients with first or multiply recurrent Clostridioides difficile infectionJessica A Bryant, Timothy J Straub, Darrell S Pardi, et al.Hepatology (Baltimore, Md.)|October 19, 2011
Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutationsChristoph Neumann-Haefelin, Cesar Oniangue-Ndza, Thomas Kuntzen, et al.Gastroenterology|August 9, 2020
A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative ColitisMatthew R Henn, Edward J O'Brien, Liyang Diao, et al.Nature Medicine|April 11, 2025
Clinical translation of microbiome researchJack A Gilbert, Meghan B Azad, Fredrik Bäckhed, et al.Nature Medicine|January 6, 2026
The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiomeJessica A Bryant, Marin Vulić, Emily A Walsh, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 8, 2020
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 TrialBarbara H McGovern, Christopher B Ford, Matthew R Henn, et al.Pageof 7